XML 105 R23.htm IDEA: XBRL DOCUMENT
v3.22.4

Earnings per Share | 12 Months Ended
--- | ---
Dec. 31, 2022
Earnings Per Share [Abstract] |
Earnings per Share |
Note 15: | Earnings per Share
Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Numerator: |  |  |  |  |  |
Net income attributable to Biogen Inc. |  | $ | 3,046.9 |  |  | $ | 1,556.1 |  |  | $ | 4,000.6 |
Denominator: |  |  |  |  |  |
Weighted average number of common shares outstanding |  | 145.3 |  |  | 149.1 |  |  | 160.9 |
Effect of dilutive securities: |  |  |  |  |  |
Time-vested restricted stock units |  | 0.5 |  |  | 0.3 |  |  | 0.2 |
Market stock units |  | 0.1 |  |  | 0.1 |  |  | 0.1 |
Performance stock units settled in stock |  | 0.1 |  |  | 0.1 |  |  | 0.1 |
Dilutive potential common shares |  | 0.7 |  |  | 0.5 |  |  | 0.4 |
Shares used in calculating diluted earnings per share |  | 146.0 |  |  | 149.6 |  |  | 161.3 |
Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant. Earnings per share for the years ended December 31, 2022, 2021 and 2020, reflects the repurchase of approximately 3.6 million shares, 6.0 million shares and 22.4 million shares of our common stock, respectively, under our share repurchase programs. For additional information on our share repurchase programs, please read Note 14, Equity, to these consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration